David P. Southwell, Chief Executive Officer at TScan Therapeutics, Inc. (TCRX), bought 25,000 shares at $3.62 ($90K) on 2022-05-18, disclosed to the SEC on 2022-05-20.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $3.55 | 10,000 | $36K | 39.5% |
| 2 | $3.62 | 15,000 | $54K | 60.5% |
| Total | $3.59 avg | 25,000 | $90K | 100% |
| Filing → |
| PTCT | SELL | 2023-04-19 | $1.2M | — | Filing → |
| PTCT | SELL | 2023-04-04 | $257K | — | Filing → |
| PTCT | SELL | 2023-03-29 | $897K | — | Filing → |